key: cord-0782788-mkn3baep
authors: Breglio, Kimberly F.; Sarver, Melissa M.; Hall, Russell P.; Marano, Anne L.
title: SARS-CoV-2 infections in patients with autoimmune blistering disorders: a case series and retrospective analysis
date: 2022-01-24
journal: JAAD Int
DOI: 10.1016/j.jdin.2022.01.003
sha: 99938c2102d4c84a5f8ad0fabf4f10056bee909a
doc_id: 782788
cord_uid: mkn3baep

Background Autoimmune blistering disorders (AIBD) are rare, potentially life-threatening conditions often requiring immunosuppression. Throughout the SARS-CoV-2 pandemic, infection risk and mortality in AIBD patients is unknown. Objective We report outcomes of SARS-CoV-2 infections in AIBD patients and determined if patients on rituximab have increased risk of SARS-CoV-2 infection. Methods We examined clinical outcomes in ten AIBD patients who developed SARS-CoV-2 infections at an American hospital. We performed a retrospective analysis of 132 AIBD patients enrolled in a clinical trial. Results Patients with severe SARS-CoV-2 (n = 4) or death (n = 2) trended older. These patients had higher mortality than the national average (20% vs 1.6%). Our cohort included 52 patients with a history of rituximab treatment, 35 of whom were immunosuppressed by rituximab during the pandemic, and 45 patients never treated with rituximab. We found no difference between rates of SARS-CoV-2 positivity in AIBD patients immunosuppressed by rituximab compared to those not on rituximab (9.1% vs 12.1%). Limitations Testing for SARS-CoV-2 was performed on demand rather than surveillance. Overall transmission varied over time and outcomes depended on accepted treatments. The small sample size of our cohort limits the generalizability of our results. Conclusion This study suggests that rituximab may not increase the risk of SARS-CoV-2 test positivity in AIBD patients. However, these results should be interpreted with caution due to our relatively small sample size.

Background: Autoimmune blistering disorders (AIBD) are rare, potentially life-threatening 25 conditions often requiring immunosuppression. Throughout the SARS-CoV-2 pandemic, 26 infection risk and mortality in AIBD patients is unknown. 27

Objective: We report outcomes of SARS-CoV-2 infections in AIBD patients and determined if 28 patients on rituximab have increased risk of SARS-CoV-2 infection. 29

Methods: We examined clinical outcomes in ten AIBD patients who developed SARS-CoV-2 30 infections at an American hospital. We performed a retrospective analysis of 132 AIBD patients 31 enrolled in a clinical trial. 32

Results: Patients with severe SARS-CoV-2 (n = 4) or death (n = 2) trended older. These patients 33 had higher mortality than the national average (20% vs 1.6%). Our cohort included 52 patients 34 with a history of rituximab treatment, 35 of whom were immunosuppressed by rituximab during 35 the pandemic, and 45 patients never treated with rituximab. We found no difference between 36 rates of SARS-CoV-2 positivity in AIBD patients immunosuppressed by rituximab compared to 37 those not on rituximab (9.1% vs 12.1%). 38 mortality from SARS-CoV-2 than the general population. 48  We did not observe increased frequency of SARS-CoV-2 in patients with autoimmune 49 blistering disorders treated with rituximab. CoV-2 pandemic has brought to light many questions regarding risk of infection, morbidity, and 56 mortality in patients with comorbid diseases as well as those on systemic immunosuppressants. 57

Autoimmune blistering disorders are rare, life-threatening conditions that include bullous 58 pemphigoid, pemphigus vulgaris, pemphigus vulgaris, mucous membrane pemphigoid, 59 epidermolysis bullous acquisita, and linear IgA disease, among others. These infections cause 60 disruption of the epidermal barrier due to the formation of blisters and erosions of the skin and 61 mucosa due to aberrant immune responses against proteins involved in cell-to-cell adhesion. 62

The role of immunosuppression in SARS-CoV-2 infections is controversial and complex in 68 regards to risk of infection and risk of severe infection. Immune-modulating and anti-69 inflammatory drugs have been used in attempts to decrease the body's aberrant immune response 70 to SARS-CoV-2 infection that has been associated with severe disease including acute 71 respiratory distress syndrome (ARDS). Corticosteroids were shown to improve outcomes in 72 patients hospitalized with SARS-CoV-2 infections. 1 We present a case series of patients with blistering disorders and SARS-CoV-2 infection. In 89 addition, we conducted a retrospective analysis of patients with autoimmune blistering disorders 90 who underwent testing for SARS-CoV-2 infection. Our primary objective in this study was to 91 report the outcomes of patients with AIBD and SARS-CoV-2 to elucidate trends in severity as 92 compared to the general population. Our secondary objective was to gather and examine existing 93 data regarding rituximab infusions to observe trends in test positivity in severely 94 immunosuppressed patients. One goal was to help clinicians make decisions regarding risks and 95 benefits of starting a rituximab infusion during the pandemic. Table  120 1. Of those who were infected, four had severe infections requiring hospitalization, two of whom 121 died. Five patients were symptomatic but did not require hospitalization. One patient had a 122 positive SARS-CoV-2 test, but no other information regarding their infection was available 123 through chart review. The median age of those who died was 88 years, those with severe disease 124 but not death was 61 years, and those with mild or asymptomatic disease was 54 years. Only one 125 patient had documented vaccination to SARS-CoV-2 (infection approximately 6 months after 126 second vaccination), though the vaccination status of two patients is unknown. 127

Regarding immunosuppression, one patient (age 62) had two, 1000mg rituximab infusions 128 spread two weeks apart within two months of their SARS-CoV-2 infection and did not require 129 hospitalization. Seven patients were on prednisone (range of 5mg-10mg daily) during their 130 SARS-CoV-2 infections. Two patients on prednisone did not require hospitalization for SARS-131

CoV-2 (ages 73 and 83), and one had a positive test with no reported symptoms (age 45). Two 132 patients on prednisone (ages 63 and 59) required hospitalization and admission to intensive care 133 unit due to their SARS-CoV-2 infection. The 59-year-old patient was enrolled in a clinical trial 134 for the treatment of pemphigus (NCT03762265) that has not been unblinded, so it is unknown 135 whether this patient was taking placebo or the study drug rilzabrutinib, an oral BTK inhibitor.

Two patients died from SARS-CoV-2, one patient on prednisone only (age 95) and one on both 138 mycophenolate mofetil and prednisone who also had comorbid COPD (age 81). 139

In order to produce a denominator of number of SARS-CoV-2 tests in AIBD patients, we In this small case series and retrospective cohort study, we observed that AIBD patients with 169 SARS-CoV-2 infections had a higher mortality rate than the general population. We also 170 observed that AIBD patients immunosuppressed by rituximab did not have increased frequency 171 of SARS-CoV-2 test positivity compared with AIBD patients not taking rituximab. Our study had several limitations. As discussed above, this is a small case series owing to AIBD 211 encompassing relatively rare diseases. These SARS-CoV-2 cases occurred at a single quaternary 212 care center and thus there may be referral bias for more severe cases. Many of these patients 213 developed SARS-CoV-2 infections prior to the development of vaccines specific for SARS-214

CoV-2; therefore, data on outcomes of infections in vaccinated AIBD patients is not presented 215 here. As discussed, patients with recent rituximab infusions did not undergo surveillance testing 216 longitudinally. The SARS-CoV-2 tests included in this study were only those performed at Duke 217 University Hospital, clinics, and testing sites. We were unable to include data from the many 218 other sources of tests including local pharmacies and health departments. Table 1 : Summary of patients with autoimmune blistering disorders and SARS-CoV-2 infections 308 

Hospitalized Patients with Covid-19

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England 271 journal of medicine 2021

Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal of 274 medicine 2020

Characteristics and 276 outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort 277 study

COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort 280 study

Characteristics of and Important Lessons From the Coronavirus 282

COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the 283

Chinese Center for Disease Control and Prevention

after Rituximab Treatment in Idiopathic Nephrotic Syndrome

Immunreconstitution and infectious complications after 288 rituximab treatment in children and adolescents: what do we know and what can we learn from 289 adults?

COVID-19 North Carolina Dashboard. COVID-19 Response

CR. COVID-19 Dashboard: Johns Hopkins University & Medicine

CR. Mortality analyses: Johns Hopkins University & Medicine

Adaptive immunity to SARS-CoV-2 and COVID-19

High rates of severe disease and death due to SARS-CoV-2 infection 297 in rheumatic disease patients treated with rituximab: a descriptive study

Expert 300 recommendations for the management of autoimmune bullous diseases during the COVID-19 301 pandemic

Determinants of COVID-19 preventive behaviours 303 among adults with chronic diseases in the USA: an analysis of the nationally representative 304 COVID-19 impact survey

Severe SARS-CoV-2 defined in the text. *Current treatment counted as rituximab within the 309 prior 12 months or any other immunosuppressive treatment for autoimmune blistering disease 310 which was given within 2 months prior to SARS-CoV-2 infection